Improving proatherogenic lipid levels, including TG and APO-B, may reduce CV events32, and the recognition of APO-C3 as an independent risk factor for atherosclerosis has led to renewed interest in APO-C3 as therapeutic target. This evidence concerns the gene C3 and atherosclerosis.